NASDAQ · AIMD
Healthcare · Biotechnology
$1.48
Down-$0.05 (-3.38%)
Updated Sep 10, 2026, 11:33 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AIMD closed at $1.48 after 20 trading sessions, down 0.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $1.49 | $1.52 | $1.46 | $1.48 | 34.23K |
| Sep 8, 2026 | $1.60 | $1.60 | $1.475 | $1.48 | 41.54K |
| Sep 4, 2026 | $1.57 | $1.65 | $1.5108 | $1.60 | 46.68K |
| Sep 3, 2026 | $1.64 | $1.67 | $1.5548 | $1.56 | 38.8K |
| Sep 2, 2026 | $1.40 | $1.60 | $1.40 | $1.58 | 89.47K |
| Sep 1, 2026 | $1.39 | $1.3957 | $1.375 | $1.39 | 4.82K |
| Aug 31, 2026 | $1.39 | $1.40 | $1.37 | $1.40 | 12.39K |
| Aug 28, 2026 | $1.42 | $1.44 | $1.38 | $1.41 | 10.83K |
| Aug 27, 2026 | $1.43 | $1.445 | $1.40 | $1.42 | 11.19K |
| Aug 26, 2026 | $1.42 | $1.46 | $1.4168 | $1.42 | 7.09K |
| Aug 25, 2026 | $1.40 | $1.45 | $1.3752 | $1.45 | 7.95K |
| Aug 24, 2026 | $1.42 | $1.44 | $1.37 | $1.39 | 11.49K |
| Aug 21, 2026 | $1.47 | $1.47 | $1.40 | $1.43 | 16.36K |
| Aug 20, 2026 | $1.48 | $1.48 | $1.40 | $1.45 | 15.53K |
| Aug 19, 2026 | $1.48 | $1.48 | $1.38 | $1.48 | 31.05K |
| Aug 18, 2026 | $1.48 | $1.48 | $1.37 | $1.40 | 39.69K |
| Aug 17, 2026 | $1.39 | $1.50 | $1.38 | $1.42 | 188.36K |
| Aug 14, 2026 | $1.44 | $1.555 | $1.40 | $1.42 | 21.19K |
| Aug 13, 2026 | $1.495 | $1.51 | $1.42 | $1.44 | 14.39K |
| Aug 12, 2026 | $1.51 | $1.54 | $1.45 | $1.49 | 42.63K |
The latest Smart Investors Daily articles mentioning AIMD.
AIMD research
Company profile and research snapshot.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 17, 2026
Ainos, Inc. (NASDAQ:AIMD, AIMDW)) ("Ainos" or the "Company"), a pioneer in AI-powered Chemical Intelligence, today announced the next generation of its AI Nose platform, featuring comprehensive upgrades
Yahoo · Aug 13, 2026
Dataset expands by approximately 265 million data points since July 21 as continued AI Nose system deployment across semiconductor manufacturing environments accelerates Ainos' Real-World Data Flywheel and Chemical Intelligence development HOUSTON, ...
Benzinga · Aug 13, 2026
Dataset expands by approximately 265 million data points since July 21 as continued AI Nose system deployment across semiconductor manufacturing environments accelerates Ainos' Real-World Data Flywheel and Chemical
Yahoo · Aug 12, 2026
AI Nose and Atmosphere Engine bring a new layer of environmental perception to intelligent machines HOUSTON, TX / ACCESS Newswire / August 12, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it will showcase ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AIMD.
